ClinicalTrials.gg
Not yet recruitingNCT07438873HIPlycraUpdated Feb 27, 2026

Dynamic Lycra Garments for Hip Dysplasia Feasibility Study

An interventional study of Lycra Shorts in Hip Dysplasia and Hypermobility Syndrome, sponsored by Royal National Orthopaedic Hospital NHS Trust. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Royal National Orthopaedic Hospital NHS Trust · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Dynamic lycra garments are deployed in rehabilitation and exercise to support unstable areas of the body, enhance sensory feedback to improve movement patterns, reduce fatigue and pain and improve function.

2 case studies have respectively highlighted the effective use of postural correction to reduce hip pain in an adult with acetabular dysplasia while lycra orthoses have reduced pain and improved stability in the hip. Larger scale studies assessing the effect of lycra garments across a clinical population of those presenting with combined hypermobility and hip dysplasia are needed to investigate the extent of generalisable effects.

The research question underpinning the project is as follows,"Can the use of dynamic compression shorts during daily activities improve short term treatment outcomes in hip dysplasia patients?".

The intention of this single cohort, observational pilot is primarily to establish the feasibility of studying the effect of the garments and assess the justification for further quantitative study, rather than the adjunctive effect of the shorts themselves.

The investigators are aiming to recruit 8-10 participants who will form a single cohort for observation, with the aim of gathering chiefly qualitative outcomes. This feasibility study is not intended to be blinded.

Read the detailed description

The Royal National Orthopaedic Hospital (RNOH) Adult Hip service treats many patients with hypermobility and hip dysplasia, the burden of both conditions including joint pain and instability affecting function and quality of life. Evidence suggests a highly significant association between these conditions.

Dynamic lycra garments are deployed in rehabilitation and exercise to support unstable areas of the body, enhance sensory feedback to improve movement patterns, reduce fatigue and pain and improve function.

A high prevalence of hypermobility has been found in populations living with hip dysplasia. 2 case studies have respectively highlighted the effective use of postural correction to reduce hip pain in an adult with acetabular dysplasia while lycra orthoses have reduced pain and improved stability in the hip. Larger scale studies assessing the effect of lycra garments across a clinical population of those presenting with combined hypermobility and hip dysplasia are needed to investigate the extent of generalisable effects.

The research question underpinning the project is as follows,"Can the use of dynamic compression shorts during daily activities improve short term physiotherapy treatment outcomes in hip dysplasia patients?".

This single cohort observational feasibility study will assess prevalence of hip dysplasia and hypermobility , refine the research protocol and measures , identify any complications of garment use, establish compliance and feedback on aspects of experience; gathering early evidence of effect and establish potential for future interventional study.

The intention of this study is primarily to establish the practicality of studying these effect of the garments over the treatment period and assess the justification for further quantitative study, rather than the adjunctive effect of the shorts themselves.

The findings will inform the development of an interventional study design which can more fully establish the generalisable degree to which this intervention can deliver effective relief from pain and disability for patients with hypermobility and hip dysplasia.

The investigators are aiming to recruit 8-10 participants with the aim of gathering chiefly qualitative outcomes. The research activities will be carried out within the Hip specialist clinic environment at the Trust Stanmore site. Prospective participants will be screened for inclusion by medical staff and then provided with a Patient Information Sheet (PIS), following which patients will be invited to a baseline measurement session with the research therapist. This feasibility study is not intended to be blinded and will be undertaken as an observational study of a single cohort.

The intervention, dynamic lycra shorts, are a Conformite Europeenne (CE) marked item which are marketed towards treating the symptoms of joint hypermobility amongst many other pathologies. No generalisable peer-reviewed evidence currently exists to support their treatment effectiveness in the current population of interest, as an adjunct to current approach which is based around exercise and education. Furthermore, qualitative aspects of use of these highly compressive lycra garments, such as impact on self-care or comfort, that could negatively impact on sustained use have not been explored in the peer-reviewed literature.

Before embarking upon a randomised trial it is important to confirm

  • the incidence of presentation of the target population, Developmental Dysplasia of the Hip (DDH) patients who are suitable for study inclusion.
  • the fraction of whom are likely to consent and then choose to remain within the study protocol until the planned conclusion.
  • extent of compliance with the intervention.
  • identify aspects of the protocol that, through researcher and participant experience, may require modification.
  • gain informed participant feedback as to the potential benefits of further research on this and similar topics.
  • the incidence of anxiety and/or depression in the target population.

The study will aim to include all adult (18+) patients with capacity and who are not classified as vulnerable individuals, who are identified as falling within the spectrum of hypermobility using validated scoring scales, with hip dysplasia signs deemed suitable for conservative care by the RNOH Hip Service medical team, and who are not under other current or planned treatments within the study duration that could affect the study outcomes. Individuals with a history of hip surgery or trauma to the hip will aso be excluded.

No upper age limit is applied. Those with identified co-morbidity including age-related degenerative changes to the hip which may obscure the effects of interest in the study may be excluded where clearly justified.

It will be made plain that each participant is free to withdraw from the study at any time without the need to provide a reason.

At the medical interview, these individuals will be provided with an information sheet and invited to contact the research team to signal their informed consent to take part in the study.

As physical attendance is required at the baseline and follow up sessions, and following confirmatory screening participants will be able to read and sign the study consent form in the presence of the research therapist. Screening will include hypermobility scoring and questionnaire based assessment of anxiety or depression related to experience of the hip pathology. As anxiety and depression are thought to be significant confounding factors when measuring the subjective impact of surgical treatment interventions, participants will complete the Hip Anxiety and Depression Score (HADS). The investigators will, however, welcome those testing positive for these psychological factors to continue onto the study on the basis that there is no reason to believe that the effect of the proposed intervention will be different for such individuals and assessment of this factor could provide valuable information about both cofactors and treatment benefits in future study and treatment protocols.

This study is observational and will not require allocation to intervention groups.

The data for each participant will be pseudonymised by assigning an identifier code at the point of study inclusion. All information, including screening data and outcome scoring together with limited demographic information will be stored under the identifier code.

At the study conclusion each participant will be asked to complete an experience questionnaire and have the opportunity to receive a debrief of their personal study data. They will also be followed up with a questionnaire asking them to reflect upon their qualitative experience and perceived personal and generalisable benefits of current and planned research into such conservative therapies.

02

Conditions studied

  • Hip Dysplasia
  • Hypermobility Syndrome

Browse trials for

Keywords

  • Hypermobility
  • Orthotic
  • Hip dysplasia
  • Physiotherapy
  • Lycra
  • Dynamic lycra garments
03

In context

Hip Dislocation

107 studies on the registry are indexed under Hip Dislocation; 36 are open to participants now.

This study's planned enrollment of 12 is below the median of 86 across 64 interventional studies indexed under Hip Dislocation.

Browse Hip Dislocation studies →

Lead sponsor

Royal National Orthopaedic Hospital NHS Trust is the lead sponsor of 12 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or over
  • Clinical diagnosis of Develomental Dysplasia of the Hip (DDH)
  • Clinical diagnosis of hypermobility

Exclusion criteria

Exclusion Criteria:

  • Under 18 years of age
  • Clinical diagnosis of additional musculoskeletal pathology affecting hips or pelvis
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Other
    All included participants

    All screened patients will be invited to participate by the medical team, based upon the inclusion and exclusion criteria specified. If the patient agrees to attend, they will attend at the research site where the following activities will take place: 1. baseline strength testing, questionnaires and interview completion. 2. shorts measurement, standardised method. 3. shorts can be fitted from stock provided by supplier (DMO Ltd). 4. Orthosis and exercise education provided. Participants will be directed to wear the lycra shorts during all daily activity and physiotherapy exercise. During the 8-12 week home trial period each participant will complete a formatted daily exercise and lycra garment intervention diary. The outcome measures gathered at baseline and followup will include: iHOT-12 questionnaire Orthotics Prosthetics Users Survey (OPUS) satisfaction subscales Hand Dynamometer - muscle strength by hip degree of movement

    Device: Lycra Shorts

Interventions

  • DeviceLycra Shorts

    The intervention, dynamic lycra shorts, are a CE marked item which are marketed towards treating the symptoms of joint hypermobility amongst many other pathologies. The product is pre-made in 7 male and female sizes, are pulled on without zips or closures and have been designed to aid lower limb function and posture whilst increasing core and pelvic stability.

06

What researchers measure

Primary outcomes

  1. International Hip Outcome Tool (iHOT-12)

    The International Hip Outcome Tool (iHOT) was developed by Mohtadi et al as a means of assessing a patient's ability to return to an active lifestyle through obtaining subjective measures of symptoms, as well as determining emotional and social health status. Results will be reported with the unabbreviated scale title, the minimum, median and maximum values, with higher scores meaning a better outcome. The scale is between 0-100 with 0 meaning a worst score and 100 the highest/best score

    Time frame: Between baseline and end of treatment at 12 weeks

Secondary outcomes

  1. Goal Attainment Scale (GAS)

    The Goal Attainment Scale (GAS) is a method of scoring the extent to which patient"s individual goals are achieved in the course of intervention, to measure functional improvements that might not be captured by standard assessments. Unlike standardized tests, GAS allows patients to set their own, relevant goals, making it highly specific to their needs. In effect, each patient has their own outcome measure but this is scored in a standardised way as to allow statistical analysis. For each goal, 0 is the baseline score, +2 is the highest score and -2 is the lowest score Results will be reported with the unabbreviated scale title, the minimum, median and maximum values, with higher scores meaning a better outcome.

    Time frame: Between baseline and end of treatment at 12 weeks.

  2. Isometric hip muscle strength testing

    Hand-held dynamometry is a quantitative and accessible means of determining the isometric force of muscle groups. In the current context, objective and standardised measurement will allow for comparisons of condition against population norms and any changes over the duration of study. Results will be reported with the unabbreviated scale title (Newtons), the minimum, median and maximum values, with higher scores meaning a better outcome.

    Time frame: Between baseline and end of treatment at 12 weeks

Other outcomes

  1. Orthotic and Prosthetic Users Survey (OPUS) Client Satisfaction with Device (CSD)scale module (Qs 1-9)

    The Orthotic and Prosthetic Users Survey (OPUS) Client Satisfaction with Device (CSD) module is designed to measure a user's satisfaction with their prosthetic or orthotic device. The 9-item version of the OPUS CSD is focused specifically on assessment of experience of the the device's functional and physical characteristics and is rated on a Likert scale (1-5) where higher score indicates greater satisfaction/agreement):

    Time frame: Measured at single time point: conclusion of study at 12 weeks

  2. Orthotic and Prosthetic Users Survey (OPUS) Heath Quality of Life (HRQOL) STATUS

    The Orthotics and Prosthetics Users' Survey (OPUS) Health-Related Quality of Life (HRQOL) index is a 23-item, validated self-report instrument designed to assess the quality of life for individuals using orthotic or prosthetic (O\&P) devices. These cover physical, emotional, and social impacts of wearing a prosthetic or orthotic device, such as pain, restrictions in daily activities (hobbies, chores, work), social, and psychological interactions.The HRQOL uses a 5-level Likert scale (0-4) for its items. The raw aggregate score for the 23 items ranges from 0 to 92, with a higher total score indicating a better outcome (better quality of life).

    Time frame: From baseline to the follow-up interval at 12 weeks

  3. Orthotic and Prosthetic Users Survey (OPUS) Lower Extremity Functional Status (LEFS)

    The Orthotic and Prosthetic Users Survey (OPUS) Lower Extremity Functional Status (LEFS) is a patient-administered questionnaire designed to evaluate functional mobility in individuals with lower limb orthoses or prostheses. The survey contains 20 items, each scored on a 5-point ordinal scale ranging from 0 (cannot do) to 4 (no difficulty), for a total raw score of up to 80. It measures the difficulty of daily tasks, with higher scores indicating better functional ability.

    Time frame: From baseline to the follow-up interval at 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Higo A, Pearce G, Palmer S, Grant L. The value of dynamic elastomeric fabric orthoses in the management of a complex hypermobile Ehlers-Danlos syndrome patient: A case report. Clin Case Rep. 2023 Jan 16;11(1):e6821. doi: 10.1002/ccr3.6821. eCollection 2023 Jan. PubMed 36694653 ↗
  • Lewis CL, Khuu A, Marinko LN. Postural correction reduces hip pain in adult with acetabular dysplasia: A case report. Man Ther. 2015 Jun;20(3):508-12. doi: 10.1016/j.math.2015.01.014. Epub 2015 Feb 4. PubMed 25731688 ↗
  • Santore RF, Gosey GM, Muldoon MP, Long AA, Healey RM. Hypermobility Assessment in 1,004 Adult Patients Presenting with Hip Pain: Correlation with Diagnoses and Demographics. J Bone Joint Surg Am. 2020 Nov 4;102(Suppl 2):27-33. doi: 10.2106/JBJS.20.00060. PubMed 32890043 ↗
  • Finlayson J, Crockett J, Shanmugam S, Stansfield B. Lycra splinting garments for adults with intellectual disabilities who fall due to gait or balance issues: a feasibility study. J Intellect Disabil Res. 2018 May;62(5):391-406. doi: 10.1111/jir.12477. Epub 2018 Feb 14. PubMed 29441642 ↗
  • Snowdon N, Sier D, Potia T, Wheat J, Mclean S. Compression garments and fabric orthoses for rehabilitation and function: A systematic mapping review. International Journal of Therapy and Rehabilitation. 2018. 25. 655-664. DOI: 10.12968/ijtr.2018.25.12.655.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Sep 2027, 18 months later.

Of 32 interventional studies with no phase under Hip Dislocation, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 18. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Feb 27, 2026
StartEst.
Mar 3, 2026
Primary completionEst.
Sep 8, 2027
CompletionEst.
Sep 8, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07438873
Lead sponsor
Royal National Orthopaedic Hospital NHS Trust
Responsible party
Katie Monnington (Katie Monnington, Advanced Physiotherapy Practitioner, Principal Investigator, Hip Services, Royal National Orthopaedic Hospital NHS Trust, Royal National Orthopaedic Hospital NHS Trust) — Principal investigator
First posted
Feb 27, 2026
Start date
Mar 3, 2026 (estimated)
Primary completion
Sep 8, 2027 (estimated)
Completion
Sep 8, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Natasha Ajraam, BSc
Contact
rnoh.research@nhs.net
020 8909 5825
Jim Ashworth-Beaumont, PhD
Contact
jim.ashworth-beaumont@nhs.net
07985552258
Katie Monnington, BSc
principal investigator · Royal National Orthopaedic Hospital NHS Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion